Gene therapy, though primarily focused on genetic disorders, has potential applications in treating non-genetic diseases as well. For instance, certain types of cancer, while not always caused by genetic mutations inherited from parents, often involve mutations acquired during a person's lifetime. Gene therapy can be used to target these acquired genetic abnormalities. For example, by introducing genes that can help the immune system recognise and combat cancer cells. Additionally, gene therapy can also be employed to introduce genes that produce therapeutic proteins or antibodies, potentially treating a range of conditions like autoimmune diseases, infectious diseases, and even heart disease. However, the application of gene therapy in non-genetic diseases is still an area of active research and development.

The immune system's response to gene therapy vectors can significantly impact the effectiveness of the treatment. When a viral vector is introduced into the body, the immune system may recognise it as foreign and mount an immune response. This can lead to the elimination of the vector before it delivers the therapeutic gene, reducing the efficacy of the treatment. In some cases, pre-existing immunity to the viral vector, due to prior exposure to the virus, can also hinder gene therapy. Additionally, if the immune response is too strong, it could lead to adverse reactions in the patient. To mitigate these issues, strategies like using low-immunogenic vectors, administering immunosuppressive drugs, or using non-viral vectors are being explored. Understanding and managing the immune response is a critical aspect of developing safe and effective gene therapy treatments.

Gene editing technologies like CRISPR-Cas9 have revolutionised the field of gene therapy. CRISPR allows for precise and efficient editing of DNA within cells, enabling the correction of genetic mutations at their source. This technology works by using a guide RNA to direct the Cas9 enzyme to a specific location in the genome, where it can cut the DNA. This cut can then be repaired by the cell's natural repair mechanisms, which can be harnessed to introduce or correct specific genetic sequences. The precision and efficiency of CRISPR make it an incredibly powerful tool for gene therapy, allowing for targeted modifications with fewer off-target effects. It has potential applications in treating a wide range of genetic disorders, from single-gene conditions like cystic fibrosis to complex diseases like cancer.

Non-viral vectors, like lipid-based vectors and naked DNA, face several challenges in gene therapy. Their main limitation is the low efficiency of gene transfer compared to viral vectors. Non-viral vectors often have difficulty crossing the cell membrane and reaching the target location within the cell, resulting in lower levels of gene uptake and expression. Furthermore, these vectors tend to provide only transient gene expression, which means the therapeutic effect may not be long-lasting, requiring repeated treatments. Another challenge is the potential for degradation of the therapeutic DNA by cellular enzymes before it reaches the target site, reducing the effectiveness of the therapy. Despite these challenges, ongoing research is focused on improving the delivery efficiency and stability of non-viral vectors to make them more viable options for gene therapy.

Viral vectors used in gene therapy are engineered to be safe and non-pathogenic. This is achieved through a process called 'attenuation', where the virus is modified to remove its ability to cause disease. For example, in retroviral and adenoviral vectors, the disease-causing genes are replaced with therapeutic genes, while keeping the virus's ability to infect cells and deliver genetic material intact. Moreover, these vectors are also designed to be replication-deficient, meaning they cannot reproduce within the patient's body. This significantly reduces the risk of the virus reverting to a pathogenic form or causing unwanted infections. The safety of these vectors is rigorously tested in preclinical and clinical trials before they are approved for use in treatments.